Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Schizophrenia

    New Jersey

    Search
    Schizophrenia
    New Jersey
    Show Map
    Map View
    New Jersey
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      45 Schizophrenia Trials near New Jersey

      Power is an online platform that helps thousands of Schizophrenia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      OLZ/SAM vs. Olanzapine for Schizophrenia or Bipolar Disorder

      Neptune, New Jersey
      To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Major Depressive Episode, Seizure Disorder, Diabetes, Others
      Must Be Taking:Antipsychotics

      220 Participants Needed

      Evenamide for Treatment-Resistant Schizophrenia

      New York, New York
      This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Suicidal Risk, Epilepsy, Others
      Must Be Taking:Antipsychotics

      400 Participants Needed

      KarXT for Schizophrenia

      New York, New York
      This trial tests the safety and tolerability of KarXT, a combination of two drugs, in schizophrenia patients who haven't responded well to their current treatments. KarXT aims to improve symptoms and manage side effects better than existing medications. KarXT (xanomeline plus trospium) is an emerging treatment for schizophrenia, showing promise in managing total, positive, and negative symptoms.
      Stay on current meds
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Suicidal Behavior, Pregnant, Urinary Retention, Others
      Must Be Taking:Antipsychotics

      280 Participants Needed

      NBI-1117568 for Schizophrenia

      Staten Island, New York
      This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Unstable Condition, Others
      Must Not Be Taking:Antipsychotics

      800 Participants Needed

      NBI-1117568 for Schizophrenia

      Staten Island, New York
      The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Unstable Condition, Others
      Must Not Be Taking:Antipsychotics

      284 Participants Needed

      SEP-363856 for Schizophrenia

      Marlton, New Jersey
      Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Alcohol Use, Substance Use, Bipolar, Others
      Must Be Taking:Antipsychotics

      522 Participants Needed

      Digital Therapeutic for Schizophrenia

      New York City, New York
      The purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have recently completed the Click Therapeutics Randomized Clinical Trial NCT05838625.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Suicidal Ideation, Positive Drug Screening, Others
      Must Not Be Taking:Synthetic Cathinones, Synthetic Cannabinoids

      73 Participants Needed

      Digital Therapeutics for Schizophrenia

      New York, New York
      This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Other DSM-5 Diagnoses, Others
      Must Be Taking:Antipsychotics

      432 Participants Needed

      Valbenazine for Schizophrenia

      New York, New York
      The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
      Stay on current meds
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Depression, Substance Use, Others
      Must Be Taking:Antipsychotics

      442 Participants Needed

      Brexpiprazole for Adolescent Schizophrenia

      New York, New York
      To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:13 - 17

      Key Eligibility Criteria

      Disqualifiers:Delirium, Dementia, Amnesia, Others
      Must Be Taking:Antipsychotics

      295 Participants Needed

      OLZ/SAM for Schizophrenia

      Neptune, New Jersey
      This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 3
      Age:10 - 17

      Key Eligibility Criteria

      Disqualifiers:Suicide Risk, Pregnancy, Others
      Must Be Taking:OLZ/SAM

      236 Participants Needed

      Olanzapine-samidorphan + Exercise for Bipolar Disorder

      New York, New York
      This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic exercise.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Diabetes, Neurological Conditions, Others
      Must Be Taking:Antipsychotics

      30 Participants Needed

      KarXT for Schizophrenia

      Philadelphia, Pennsylvania
      The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:New Schizophrenia, Alcohol, Drug Use, Others
      Must Not Be Taking:Antipsychotics

      60 Participants Needed

      Xanomeline + Trospium for Schizophrenia

      Marlton, New Jersey
      The study design is a de-escalation of current atypical AP treatment to X/T at a maintenance dose of X/T established either at 100 mg xanomeline/20 mg trospium chloride BID (total daily dose 200 mg xanomeline/40 mg trospium chloride) or 125 mg xanomeline/30 mg trospium chloride BID (total daily dose 250 mg xanomeline/60 mg trospium chloride) based on participants' clinical response and/or tolerability. While the package insert for X/T provides guidance for clinicians on dosing, this study is designed to assess how transitioning will occur in the "real world" situation.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Cardiovascular Disease, Hepatic Impairment, Others
      Must Be Taking:Atypical Antipsychotics

      100 Participants Needed

      MT1988 for High Risk of Psychosis

      Philadelphia, Pennsylvania
      The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks. This will help identify tests that could be used in later trials developing treatments for symptoms in people at high risk of developing psychosis, to measure whether those new treatments are effective. The main question this trial aims to answer is: Can any of the tests (biomarkers) used in this study detect changes in participants dosed with one of two different dose levels of MT1988? Researchers will compare the results from two dose levels of MT1988 to a placebo group. Researchers do not expect to see the test results change in participants taking placebo and this will be compared to changes expected in test results in participants taking MT1988. Participants will: * take a dose of MT1988 or placebo twice per day for 8 weeks * attend clinic appointments every two weeks to undertake assessments * report any side effects they experience to the researchers

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 1, 2
      Age:17 - 30

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Cognitive Disorder, Suicide Risk, Others
      Must Not Be Taking:Antipsychotics, Others

      150 Participants Needed

      ANAVEX3-71 for Schizophrenia

      Marlton, New Jersey
      A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Suicidal Risk, Others
      Must Be Taking:Atypical Antipsychotics

      71 Participants Needed

      LB-102 for Schizophrenia

      Staten Island, New York
      This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives of the study are to evaluate improvement in CGI-S, safety and tolerability, and pharmacokinetics.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      350 Participants Needed

      Emraclidine for Schizophrenia

      Staten Island, New York
      This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Cardiovascular, Diabetes, Others
      Must Be Taking:Antipsychotics

      850 Participants Needed

      Levetiracetam for Early Psychosis

      New York, New York
      This is a 12-week study of levetiracetam added to a second generation antipsychotic in early psychosis patients who have been ill for less than 5 years and continue to experience psychotic symptoms despite at least 8 weeks of antipsychotic treatment. Levetiracetam (Keppra) is a medication approved for the treatment of epilepsy; it reduces excessive activity in the brain. This study will test the hypotheses that adding levetiracetam will improve psychotic symptoms that are unresponsive to antipsychotic treatment and will protect the brain from atrophy (volume loss). .

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:16 - 40

      Key Eligibility Criteria

      Disqualifiers:Substance Abuse, Mood Disorder, Suicidal Ideation, Neurological Illness, Others
      Must Be Taking:Antipsychotics

      84 Participants Needed

      KYN-5356 for Schizophrenia

      Marlton, New Jersey
      This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28. Efficacy, safety, PK and exploratory PD assessments will be performed throughout the dosing period. Participants will be discharged on Day 29 after safety assessments are completed and return for a follow-up visit on Day 42. A subset of participants from selected sites will undergo electrophysiological assessments to evaluate the effect of KYN-5356 on neurophysiological measures of brain function.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Unstable Condition, Others
      Must Be Taking:Antipsychotics

      150 Participants Needed

      Why Other Patients Applied

      "I’ve been treated over the years from my late teens. I’ve been through many therapists for my bipolar and my anxiety. None of it’s helped. I gave up when I was 27. It’s been 5 years of struggling day by day. My fiancé has finally suggested I look into trying to get help so I’m hoping this clinical trial will help."

      WZ
      Schizophrenia PatientAge: 32

      "I would like to get a medication that has fewer side effects than the ones I've used. Many antipsychotics just make me numb or flat and I can't really think. Also I like the idea of helping in research to find better medications for schizephrenia."

      VT
      Schizophrenia PatientAge: 60

      "I'm willing to try anything to help improve and manage my schizophrenia in any way. I do my best each day to keep the hallucinations at bay. I no longer hear voices but I don't want them to come back either. Most medicine I've tried hasn't help very much."

      ZC
      Schizophrenia PatientAge: 39

      "I've tried lots of drugs and I still have symptoms. I'm not sure of my reality because the things I see and hear are still active. Maybe this will help one way or the other. I would be glad to help others in the future by testing a medication as well."

      CY
      Schizophrenia PatientAge: 62

      "I’ve been diagnosed with Schizoaffective Disorder for over 5 years now and not found much relief in medication. One I’ve tried helped a bit but the side affects were overwhelming. Hoping I can gain some relief from this disorder and help advance research as well!"

      MX
      Schizophrenia PatientAge: 44
      Match to a Schizophrenia Trial

      Emraclidine for Schizophrenia

      Marlton, New Jersey
      Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Other DSM-5 Disorders, Treatment Resistance, Others
      Must Not Be Taking:Clozapine

      258 Participants Needed

      ML-007C-MA for Schizophrenia

      Staten Island, New York
      ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Others
      Must Not Be Taking:Antipsychotics

      300 Participants Needed

      ALTO-101 for Schizophrenia

      New York, New York
      This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:21 - 55

      Key Eligibility Criteria

      Disqualifiers:Unstable Condition, Bipolar, Dementia, Others
      Must Be Taking:Antipsychotics

      82 Participants Needed

      Affective Awareness for Suicide Prevention

      Bronx, New York
      This trial tests a new approach to help veterans with serious mental illness who are at risk of suicide. The treatment combines group education sessions and a smartphone app to improve emotional awareness and social functioning. By helping veterans understand their emotions better, the goal is to reduce their suicide risk.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Medical Conditions, Other Study, Others

      40 Participants Needed

      KarXT for Schizophrenia

      Marlton, New Jersey
      The purpose of this study is to evaluate the dose levels, safety, and drug levels of KarXT intramuscular injection in participants with Schizophrenia
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 55

      Key Eligibility Criteria

      Disqualifiers:New Schizophrenia, Major Depression, Others
      Must Not Be Taking:Antipsychotics

      48 Participants Needed

      TV-44749 vs Oral Olanzapine for Schizophrenia

      Marlton, New Jersey
      The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. A secondary objective of this trial is to evaluate the safety and tolerability of multiple doses of TV-44749 administered sc in participants with schizophrenia. Another secondary objective of this trial is to compare additional pharmacokinetic parameters of TV-44749 administered sc with oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia. The total duration of participation in the trial for each participant is planned to be approximately 21 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Hepatic Disorder, Arrhythmia, Others
      Must Be Taking:Olanzapine

      116 Participants Needed

      Positive Emotion Upregulation for Schizophrenia

      Piscataway, New Jersey
      The goal of this clinical trial is to learn if attention and ways of thinking impact decision-making and brain processes related to decision-making in people with schizophrenia or schizoaffective disorder relative to people without either condition. It will also learn how brain functioning during decision-making relates to real-world decisions made during daily life. The main questions it aims to answer are: * Does paying attention to specific information impact decision-making and brain processes? * Does thinking in a certain way according to specific 'thinking strategies' improve brain processes related to decision-making? * Does brain functioning during decision-making relate to real-world choices to engage in activities? Researchers will compare brain functioning and decision-making on computer tasks of gambling after participants have been trained to use a positive thinking strategy. They will compare what is different in the brain and behavior when participants use this strategy and when they do not. Participants will also answer brief surveys about activities and feelings for a week in their daily lives. Participants will: * Complete several hours of clinical interviewing, cognitive tests, and surveys of about symptoms, experiences, and personality * Complete computer tasks about gambling decisions during MRI brain scanning and while having their visual attention measured using eye-tracking * Complete brief surveys about their activities and feelings 5 times a day for 1 week using a cell phone. Each survey only take several minutes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 45

      Key Eligibility Criteria

      Disqualifiers:Substance Use, Neurological Disease, Epilepsy, Others

      74 Participants Needed

      Behavioral Activation for Serious Mental Illness

      Philadelphia, Pennsylvania
      The goal of this study is to evaluate the effectiveness of an behavioral activation intervention to increase meaningful activity and community participation for people with serious mental illness. The overall objective of this study is to increase engagement in meaningful activities and community participation. The objectives of the project are as follows: 1. To determine if the intervention leads to increases the frequency and variety of activities. 2. To determine if the intervention leads to increases in community mobility. 3. To determine which demographic and environmental factors and mechanisms of action impact the effectiveness of the intervention. 4. To determine if the the intervention leads to an improvement in overall well-being (e.g., improved quality of life). Participants will be asked to attend a 2-hour weekly online session for 10 weeks and then a 1-hour online monthly session for a 3 month maintenance period. For data collection, participants will also be asked to: 1. Complete three, approximately 1-hour interviews at baseline, after the 10 week intervention, and again at the end of the maintenance period; 2. Carry a mobile phone with a global positioning system app to track their movements outside their home for 2 weeks at a time, at three separate times (e.g., baseline, after the intervention, and at the end of the maintenance period); and 3. Complete a 15 minute weekly interviews for 26 weeks about their daily activities and participation. The study will enroll 52 participants split into 4 cohorts of 13. The study will use a multiple baseline design and, as such, all participants will receive the intervention and there is no control group.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Unable To Give Consent, Legal Guardian

      52 Participants Needed

      Telehealth Cognitive Behavioral Therapy for High Risk of Psychosis

      New York, New York
      This trial tests telehealth-based Cognitive Behavioral Therapy for young people at high risk of psychosis. It aims to make therapy more accessible and effective by offering group, family, and individual sessions online. The study will measure how well these methods work in improving mental health and preventing the onset of psychosis.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:14 - 25

      Key Eligibility Criteria

      Disqualifiers:Intellectual Disability, Medical Condition, Substance Use, Others

      72 Participants Needed

      Enhanced Screening & Communication for Psychosis

      New York, New York
      The goal of this project is to investigate whether a systematic screening approach enhanced by an innovative model of communicating information about psychosis and treatment options to patients and families (ComPsych) can reduce Duration of Untreated Psychosis (DUP) by facilitating early identification of first episode psychosis (FEP) cases, rapid referral to specialty care and engagement in treatment. The study team will use a stepped-wedge cluster randomized controlled trial design to compare a systematic screening and communication method (SCM) to systematic screening method (SM) to evaluate whether SCM substantially reduces DUP. The study team hypothesize that: (1) SCM will result in a higher number of individuals initiating specialty services compared to SM; (2) The mean DUP of FEP individuals in SCM condition will be lower than the mean DUP of FEP individuals in SM condition, due to the reduced time to initiate FEP services. We will also conduct a qualitative study to examine implementation barriers and facilitators of SCM.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:12 - 30

      Key Eligibility Criteria

      Disqualifiers:Schizophrenia, Schizoaffective, Schizophreniform, Delusional

      912 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Schizophrenia clinical trials in New Jersey pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Schizophrenia clinical trials in New Jersey work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Schizophrenia trials in New Jersey 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New Jersey for Schizophrenia is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New Jersey several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Schizophrenia medical study in New Jersey?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Schizophrenia clinical trials in New Jersey?

      Most recently, we added KarXT for Schizophrenia, MT1988 for High Risk of Psychosis and Evenamide for Treatment-Resistant Schizophrenia to the Power online platform.

      Why is schizophrenia more common now?

      Most studies show the yearly number of new schizophrenia cases hasn’t skyrocketed; it only feels more common because doctors now catch milder cases and people with the illness live longer, so more are counted at any one time. Modern lifestyle changes—growing up in crowded cities, high-potency cannabis use, migration stress, older parenthood, and ongoing poverty—do add modest risk for certain groups, nudging overall figures upward. Recognising these drivers guides prevention efforts like early screening, substance-use education, urban social support, and good prenatal care.

      What is the best injection for schizophrenia?

      There isn’t one “best” injection for everyone with schizophrenia. Doctors usually choose among long-acting injectables such as paliperidone (monthly to every 6 months), aripiprazole (monthly or every 2–3 months) or risperidone (every 2 weeks to monthly) based on which oral version has helped you before, how often you can come for shots, and which side-effects you’re most sensitive to. Your psychiatrist will review these factors—plus cost, other health conditions and personal preference—to decide which LAI is the safest and most effective fit for you.

      Who is most likely to recover from schizophrenia?

      Research shows the best odds of meaningful recovery occur in people who get treatment quickly after their first symptoms, keep taking medication and using psychological/rehab supports, avoid alcohol or drugs, and have steady family or community support; women and those whose illness starts later in their 20s also tend to fare somewhat better, but these fixed factors matter less than the modifiable ones above. In short, while anyone with schizophrenia can improve, the combination of early intervention, sticking with care, healthy lifestyle, and strong social ties makes the biggest difference in who recovers.

      Is schizophrenia inherited from mother or father?

      Schizophrenia risk is passed down through many genes that you receive from both parents, and large studies do not show a consistent advantage of either the mother’s or the father’s side. Compared with the 1 % lifetime risk in the general population, the chance rises to about 10 % if one parent has schizophrenia and up to 40 % if both do; factors such as pregnancy complications, cannabis use, severe stress, or very advanced paternal age can add to that risk. Families with a history of the illness may benefit from genetic counselling and early mental-health check-ups during adolescence so any warning signs can be managed promptly.

      How is schizophrenia viewed in China?

      China does not have a single view of schizophrenia: in big cities many people now regard it as a treatable brain disorder, but in rural areas it may still be linked to spirit possession or seen as a source of family “shame,” so relatives often hide the illness and shoulder most care. High stigma persists because unusual behaviour is felt to threaten the family’s “face,” yet government programs such as the nationwide 686 follow-up system and the 2013 Mental-Health Law are expanding hospital care, community visits, and public education. Overall, attitudes are gradually shifting toward acceptance, but progress is uneven and support for both patients and their families remains a work in progress.

      Are there any clinical trials being done for schizophrenia?

      Yes—dozens of studies are actively recruiting worldwide, ranging from novel medicines like KarXT (muscarinic M1/M4 agonist), ulotaront (TAAR1 agonist), and roluperidone (aimed at negative symptoms) to long-acting weekly risperidone implants (TV-46000) and app-based cognitive programs. You can see real-time listings, eligibility criteria, and locations by typing “schizophrenia” into ClinicalTrials.gov or the EU Clinical Trials Register and then reviewing the options with your psychiatrist to weigh potential benefits, risks, and travel demands.

      What is the biggest problem of schizophrenia?

      Schizophrenia isn’t defined by one “biggest problem”; clinicians group its effects into positive symptoms (hallucinations/delusions), disorganization, negative symptoms (loss of drive, social withdrawal) and cognitive deficits. Studies show that after acute psychosis is controlled, the lasting obstacles to working, studying and maintaining relationships are usually the negative and cognitive symptoms, so effective care pairs antipsychotic medication with therapies and skills training that rebuild motivation, thinking and daily-living abilities.

      Who has the highest rate of schizophrenia?

      Worldwide, the single highest recorded rates occur in young adult Black Caribbean or Black African men who are migrants (or children of migrants) living in large urban areas; their chance of developing schizophrenia can be 4- to 9-times higher than that of white native-born residents. In general, men have a modestly higher risk than women (about 1.4 : 1), but factors such as minority or migrant status and growing up in a high-density city raise risk far more than sex alone.

      What's the latest schizophrenia can develop?

      Most people who develop schizophrenia do so between their late teens and early 30s, but experts recognise “late-onset” cases appearing at 40-60 and a rarer “very-late-onset schizophrenia-like psychosis” beginning after 60. Because psychosis this late in life is uncommon and can mimic problems such as dementia, stroke, or severe depression, anyone with new hallucinations or delusions at these ages should be evaluated promptly by a mental-health professional and a physician to sort out the cause and start the right treatment.

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Clinical Trials near Alliance, OH

      Top Clinical Trials near San Diego, CA

      Top Leiomyosarcoma Clinical Trials

      Top Acoustic Neuroma Clinical Trials

      Top Clinical Trials near East Windsor, NJ

      210 Clinical Trials near Carrollton, TX

      Top Esophagus Cancer Clinical Trials

      Top Rhabdomyosarcoma Clinical Trials

      Top Clinical Trials near Boulder, CO

      Top Clinical Trials near Clyde, NC

      Top Lipedema Clinical Trials

      Top Clinical Trials near Atlantis, FL

      By Trial

      Multiple Interventions for Orthostatic Intolerance

      Vagal Nerve Stimulation for Reducing Nasogastric Tube Use

      Trauma Focused Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder

      Bepirovirsen for HIV and Hepatitis B

      VNS for Bipolar Depression

      Geistlich Fibro-Gide® vs Connective Tissue Graft for Dental Implant Soft Tissue Enhancement

      Contrast-Enhanced Mammography for Breast Abnormalities

      Ibrutinib + Trastuzumab for Breast Cancer

      Peginterferon Beta-1a for Multiple Sclerosis

      Genetic Counseling for Breast Cancer

      Remote Genetic Counseling for Cancer Survivors

      Ipatasertib + Chemotherapy for Ovarian Cancer